Jagforce SB 130 Capsule contains Itraconazole 130 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Jagforce SB 130 Capsule is particularly effective against infections caused by dermatophytes, yeasts, and molds. The drug is administered orally and exhibits good bioavailability when taken with food, enhancing absorption. It is metabolized primarily by the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Liver function tests should be monitored during prolonged therapy. Jagforce SB 130 Capsule should be used under medical supervision, with dosage and duration tailored to the specific infection and patient condition to ensure optimal efficacy and safety.